511 related articles for article (PubMed ID: 22197088)
1. Use of fusion imaging combining contrast-enhanced ultrasonography with a perflubutane-based contrast agent and contrast-enhanced computed tomography for the evaluation of percutaneous radiofrequency ablation of hypervascular hepatocellular carcinoma.
Numata K; Fukuda H; Morimoto M; Kondo M; Nozaki A; Oshima T; Okada M; Takebayashi S; Maeda S; Tanaka K
Eur J Radiol; 2012 Oct; 81(10):2746-53. PubMed ID: 22197088
[TBL] [Abstract][Full Text] [Related]
2. Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography.
Nishigori S; Numata K; Irie K; Fukuda H; Chuma M; Maeda S
J Med Ultrason (2001); 2018 Jul; 45(3):405-415. PubMed ID: 29362966
[TBL] [Abstract][Full Text] [Related]
3. Radiofrequency ablation of hepatocellular carcinoma: value of virtual CT sonography with magnetic navigation.
Minami Y; Chung H; Kudo M; Kitai S; Takahashi S; Inoue T; Ueshima K; Shiozaki H
AJR Am J Roentgenol; 2008 Jun; 190(6):W335-41. PubMed ID: 18492875
[TBL] [Abstract][Full Text] [Related]
4. Role of Sonazoid-enhanced three-dimensional ultrasonography in the evaluation of percutaneous radiofrequency ablation of hepatocellular carcinoma.
Luo W; Numata K; Morimoto M; Oshima T; Ueda M; Okada M; Takebayashi S; Zhou X; Tanaka K
Eur J Radiol; 2010 Jul; 75(1):91-7. PubMed ID: 19361941
[TBL] [Abstract][Full Text] [Related]
5. Use of intra-procedural fusion imaging combining contrast-enhanced ultrasound using a perflubutane-based contrast agent and auto sweep three-dimensional ultrasound for guiding radiofrequency ablation and evaluating its efficacy in patients with hepatocellular carcinoma.
Sanga K; Numata K; Nihonmatsu H; Ogushi K; Fukuda H; Chuma M; Hashimoto H; Koizumi N; Maeda S
Int J Hyperthermia; 2020; 37(1):202-211. PubMed ID: 32070164
[No Abstract] [Full Text] [Related]
6. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas.
Yoon JH; Lee EJ; Cha SS; Han SS; Choi SJ; Juhn JR; Kim MH; Lee YJ; Park SJ
J Vasc Interv Radiol; 2010 Mar; 21(3):348-56. PubMed ID: 20116285
[TBL] [Abstract][Full Text] [Related]
7. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma.
Numata K; Fukuda H; Miwa H; Ishii T; Moriya S; Kondo M; Nozaki A; Morimoto M; Okada M; Takebayashi S; Maeda S; Nozawa A; Nakano M; Tanaka K
Eur J Radiol; 2014 Jan; 83(1):95-102. PubMed ID: 24176532
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic response assessment of percutaneous radiofrequency ablation for hepatocellular carcinoma: utility of contrast-enhanced agent detection imaging.
Kim CK; Choi D; Lim HK; Kim SH; Lee WJ; Kim MJ; Lee JY; Jeon YH; Lee J; Lee SJ; Lim JH
Eur J Radiol; 2005 Oct; 56(1):66-73. PubMed ID: 15913940
[TBL] [Abstract][Full Text] [Related]
9. Radiofrequency ablation of hepatocellular carcinoma: therapeutic response using contrast-enhanced coded phase-inversion harmonic sonography.
Wen YL; Kudo M; Zheng RQ; Minami Y; Chung H; Suetomi Y; Onda H; Kitano M; Kawasaki T; Maekawa K
AJR Am J Roentgenol; 2003 Jul; 181(1):57-63. PubMed ID: 12818830
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the therapeutic efficacy of high-intensity focused ultrasound ablation of hepatocellular carcinoma by three-dimensional sonography with a perflubutane-based contrast agent.
Numata K; Fukuda H; Ohto M; Itou R; Nozaki A; Kondou M; Morimoto M; Karasawa E; Tanaka K
Eur J Radiol; 2010 Aug; 75(2):e67-75. PubMed ID: 20015603
[TBL] [Abstract][Full Text] [Related]
11. Contrast-enhanced ultrasound in the characterization of hepatocellular carcinomas treated by ablation: comparison with contrast-enhanced magnetic resonance imaging.
Qu P; Yu X; Liang P; Cheng Z; Han Z; Liu F; Yu J
Ultrasound Med Biol; 2013 Sep; 39(9):1571-9. PubMed ID: 23830098
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of CT/MR-US fusion imaging for radiofrequency ablation of hepatic nodules.
Lee JY; Choi BI; Chung YE; Kim MW; Kim SH; Han JK
Eur J Radiol; 2012 Sep; 81(9):2281-9. PubMed ID: 21937177
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of contrast-enhanced US versus CT or MRI for the therapeutic control of percutaneous radiofrequency ablation in the case of hepatic malignancies.
Frieser M; Kiesel J; Lindner A; Bernatik T; Haensler JM; Janka R; Hahn EG; Strobel D
Ultraschall Med; 2011 Apr; 32(2):148-53. PubMed ID: 21225567
[TBL] [Abstract][Full Text] [Related]
14. Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy?
Watanabe H; Kanematsu M; Goshima S; Yoshida M; Kawada H; Kondo H; Moriyama N
AJR Am J Roentgenol; 2012 Mar; 198(3):589-95. PubMed ID: 22357997
[TBL] [Abstract][Full Text] [Related]
15. Treatment response assessment of radiofrequency ablation for hepatocellular carcinoma: usefulness of virtual CT sonography with magnetic navigation.
Minami Y; Kitai S; Kudo M
Eur J Radiol; 2012 Mar; 81(3):e277-80. PubMed ID: 21392916
[TBL] [Abstract][Full Text] [Related]
16. Image-guided radiofrequency ablation of hepatocellular carcinoma (HCC): is MR guidance more effective than CT guidance?
Clasen S; Rempp H; Hoffmann R; Graf H; Pereira PL; Claussen CD
Eur J Radiol; 2014 Jan; 83(1):111-6. PubMed ID: 24161781
[TBL] [Abstract][Full Text] [Related]
17. Percutaneous radiofrequency ablation of malignant liver tumors with ultrasound and CT fusion imaging guidance.
Xu ZF; Xie XY; Kuang M; Liu GJ; Chen LD; Zheng YL; Lu MD
J Clin Ultrasound; 2014; 42(6):321-30. PubMed ID: 24615771
[TBL] [Abstract][Full Text] [Related]
18. CT-guided radiofrequency ablation for hepatocellular carcinomas that were undetectable at US: therapeutic effectiveness and safety.
Park BJ; Byun JH; Jin YH; Won HJ; Shin YM; Kim KW; Park SJ; Kim PN
J Vasc Interv Radiol; 2009 Apr; 20(4):490-9. PubMed ID: 19328427
[TBL] [Abstract][Full Text] [Related]
19. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma.
Takizawa K; Numata K; Morimoto M; Kondo M; Nozaki A; Moriya S; Ishii T; Oshima T; Fukuda H; Okada M; Takebayashi S; Maeda S; Tanaka K
Eur J Radiol; 2013 Sep; 82(9):1471-80. PubMed ID: 23769188
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of three-dimensional Gd-EOB-DTPA-enhanced MR fusion imaging with CT fusion imaging in the assessment of treatment effect of radiofrequency ablation of hepatocellular carcinoma.
Makino Y; Imai Y; Igura T; Hori M; Fukuda K; Sawai Y; Kogita S; Fujita N; Takehara T; Murakami T
Abdom Imaging; 2015 Jan; 40(1):102-11. PubMed ID: 25052767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
